Mark Powis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark Powis has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kathy Pritchard-Jones
Developmental Biology and Cancer Research and Teaching Department UCL Great Ormond Street Institute of Child Health University College London London UK
2 shared publications Anna Kelsey
Department of Paediatric Pathology, Royal Manchester Children's Hospital, Manchester, UK
1 shared publicationBoo Messahel
1 shared publicationCharles A. Stiller
Childhood Cancer Research Group, University of Oxford, Oxford, UK
1 shared publicationGordan M. Vujanic
Department of Histopathology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
1 shared publicationH Carter
Department of Paediatric Surgery, United Leeds Teaching Hospitals Leeds, UK
1 shared publication
Latest Publications
- 16 January 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (5) , 744-748
Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG)
Background: Mesoblastic nephroma (MN) is a rare tumour which occurs mainly in early infancy and for which primary nephrectomy is the treatment of choice. This study aimed to assess surgical complications and outcomes in this patient group and to re‐evaluate the age threshold of 6 months for recommending primary nephrectomy.Procedure: A retrospective file review of all cases of MN registered in UK Children's Cancer and Leukaemia Group renal tumour trials between October 1991 and March 2008. Data from the trials were compared with data held by the National Registry of Childhood Tumours, Oxford.Results: Forty‐seven (3.5%) confirmed cases of MN were found among 1346 registered renal tumours. Median age at diagnosis was 30 days (range birth‐3.8 years). MN was significantly more common in the first 3 months of life compared to between 3 and 6 months (33 vs. 2 cases). Seven cases occurred between 6 months and 1 year and only five cases occurred beyond 1 year of age. There was a significant difference in the age of diagnosis by histological subtype. There were 11 complications in the series; no registered patient developed a recurrent tumour; and all were alive at last follow‐up.Conclusions: Outcome for children with MN is excellent at all ages, with little indication for adjuvant chemotherapy. Children presenting at 3 months, alternative diagnoses should be considered, especially in the presence of surgical risk factors. Pediatr Blood Cancer 2011;56:744–748.
- 16 January 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (5) , 744-748
Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG)
Background: Mesoblastic nephroma (MN) is a rare tumour which occurs mainly in early infancy and for which primary nephrectomy is the treatment of choice. This study aimed to assess surgical complications and outcomes in this patient group and to re‐evaluate the age threshold of 6 months for recommending primary nephrectomy.Procedure: A retrospective file review of all cases of MN registered in UK Children's Cancer and Leukaemia Group renal tumour trials between October 1991 and March 2008. Data from the trials were compared with data held by the National Registry of Childhood Tumours, Oxford.Results: Forty‐seven (3.5%) confirmed cases of MN were found among 1346 registered renal tumours. Median age at diagnosis was 30 days (range birth‐3.8 years). MN was significantly more common in the first 3 months of life compared to between 3 and 6 months (33 vs. 2 cases). Seven cases occurred between 6 months and 1 year and only five cases occurred beyond 1 year of age. There was a significant difference in the age of diagnosis by histological subtype. There were 11 complications in the series; no registered patient developed a recurrent tumour; and all were alive at last follow‐up.Conclusions: Outcome for children with MN is excellent at all ages, with little indication for adjuvant chemotherapy. Children presenting at 3 months, alternative diagnoses should be considered, especially in the presence of surgical risk factors. Pediatr Blood Cancer 2011;56:744–748.
- 1 October 2010
- Published by Elsevier in Early Human Development
- Vol. 86 (10) , 607-612
Neonatal renal tumours
- 1 October 2010
- Published by Elsevier in Early Human Development
- Vol. 86 (10) , 607-612
Neonatal renal tumours
- 1 October 2006
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 88 (6) , 607
Further Information on a Simple Method for Securing a Surgical Drain
- 1 October 2006
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 88 (6) , 607
Further Information on a Simple Method for Securing a Surgical Drain